18h
Investor's Business Daily on MSNBehind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats UpHims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...
Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.
Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...
It's frustrating, but you're not alone! As we get older, our bodies don't respond the same way to weight loss efforts, and science has some explanations to offer. As we age we naturally tend to ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
As original Medicare faces funding shortfalls, Dr. Oz may shift to private insurance providers through Medicare Advantage.
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
Medicare Part D spending for 10 selected diabetes drugs totaled more than $35.8 billion in 2023, a 364% increase from 2019, according to a new data brief from the Department of Health and Human Servic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results